Collegium Pharmaceutical (NASDAQ:COLL) Raised to “Buy” at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a note issued to investors on Friday, MarketBeat reports. The brokerage currently has a $46.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 39.78% from the company’s current price.

COLL has been the topic of several other research reports. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler reiterated a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.80.

Collegium Pharmaceutical Stock Down 1.3 %

Shares of NASDAQ:COLL opened at $32.91 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a 50 day simple moving average of $30.56 and a 200-day simple moving average of $34.05. The company has a market capitalization of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Penserra Capital Management LLC purchased a new stake in shares of Collegium Pharmaceutical in the third quarter valued at about $757,000. Barclays PLC lifted its holdings in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after buying an additional 45,291 shares during the period. Squarepoint Ops LLC boosted its stake in shares of Collegium Pharmaceutical by 194.5% in the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after buying an additional 72,874 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 8.0% during the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after acquiring an additional 113,300 shares during the period. Finally, BOKF NA acquired a new stake in Collegium Pharmaceutical in the second quarter valued at $490,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.